Webinar: Discovering Tumor Metabolic Signatures in FFPE Tissues Register Now

Metabolomics and Drug Response: Why Patients Differ

Can Metabolomics Explain Differences in Drug Response? How much does our environment influence our health—and what could that mean for precision medicine? Why does a drug work well for some patients but have little effect on others? Differences in underlying disease biology may hold important clues. In this episode of ChatGJP, Panome Bio CSO Gary […]

Breast Cancer FFPE Metabolomics

Metabolic Profiling of Breast Cancer in FFPE Tissue and Plasma See how TissueBridge™ FFPE Metabolomics can be used to characterize metabolic patterns across breast cancer disease stages by analyzing archived tumor tissue alongside plasma samples. The analysis identified distinct metabolic patterns across Stage I and Stage II+ samples, including changes in sphingolipid and amino acid […]

TissueBridge™ FFPE Proteomics of CRC Tumor Tissue Biopsies

This data report demonstrates the capabilities of Panome Bio’s TissueBridge™ FFPE Proteomics, showcasing comprehensive protein profiling from formalin-fixed, paraffin-embedded (FFPE) tissue. The report includes protein identification, differential protein expression analysis, pathway enrichment and biological interpretation generated from archived tissue specimens. It highlights how TissueBridge™️ enables robust, reproducible proteomic analysis of FFPE samples.

Illustration of synergistic cancer therapy showing combination drug treatment inducing metabolic stress in tumor cells

A Metabolic Blueprint for Synergistic Cancer Therapy

In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. These challenges are fueling a critical shift in oncology towards combination therapies that target cancer from multiple angles. […]

Metabolomics for Mechanism of Action: Understanding Drivers of Synergistic Inhibitor Treatment in Cancer

Metabolomics for Mechanism of Action in Synergistic Cancer Treatments Next-Generation Metabolomics can provide robust, biologically meaningful data for drug combination analysis. Learn more about treatment-induced metabolic reprogramming and targeted combination therapies in this case study. This application note has been redesigned with updated figures for improved clarity. The underlying analysis and conclusions remain the same.

PRMT5 Metabolomics Panel for Patient Stratification

PRMT5 Metabolomics Panel for Patient Stratification This poster presents a targeted, multiplexed LC-MS/MS metabolomics assay developed to support patient stratification and pharmacodynamic monitoring for MTA-cooperative PRMT5 inhibitors in oncology research. Leveraging Panome Bio’s specialized PRMT5 metabolomics panel, the assay enables sensitive and quantitative measurement of key metabolites associated with methylthioadenosine (MTA) biology and PRMT5 pathway […]

The Hidden Metabolic Information of FFPE Tissue

For decades, Formalin-Fixed Paraffin-Embedded (FFPE) tissue has been the standard for preserving clinical samples. From cancer biopsies to organ tissue, this method is used across hospitals and research centers worldwide to store biological material for long-term use and histological analysis. FFPE tissue’s unmatched stability and compatibility with microscopy makes it a valuable resource for retrospective […]

Metabolomics in ADC & Immuno-Oncology

Payload to Patient: Metabolomics in ADC and Immuno-Oncology In this episode of the ChatGJP series, Panome Bio CSO Dr. Gary J. Patti joins Chris Eden to explore real-world applications of metabolomics in antibody–drug conjugates (ADCs) and immuno-oncology. The discussion covers how untargeted metabolomics can identify early biomarkers of drug efficacy and toxicity, stratify tumors based […]

Integrated Multi-Omic Analysis of KRAS Colorectal Cancer

Integrated Multi-Omic Analysis of KRAS-Driven Colorectal Cancer This poster presents an integrated multi-omic analysis of colorectal cancer models driven by the KRAS mutation. By combining global metabolomics, proteomics, phosphoproteomics, and transcriptomics, the study reveals critical metabolic dependencies and pathway-level vulnerabilities associated with altered KRAS activity. The findings highlight modules of dysregulation related to EGFR signaling, […]

Comprehensive PRMT5 Activity Profiling in Cancer

From Metabolism to Mechanism, Profile PRMT5 Activity in Cancer Profile PRMT5 activity with precise SDMA/ADMA quantification and full methionine cycle coverage. Support inhibitor development, patient stratification, and tumor profiling.

Skip to content